[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100442360":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":24,"responsibleParty":86,"collaborators":10,"id":88,"slug":10,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":10,"eligibilityCriteria":93,"healthyVolunteers":89,"sex":94,"minAge":10,"maxAge":10,"enrollmentInfo":95,"targetDuration":10,"studyType":98,"phases":10,"briefSummary":99,"conditions":100,"keywords":103,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"Alnylam Pharmaceuticals","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patisiran",null,"Pregnant women exposed to commercial patisiran-LNP (ONPATTRO) during the 12 weeks prior to their last menstrual period (LMP) or at any time during pregnancy.",[13],{"name":14,"affiliation":5,"role":15},"Medical Director","STUDY_DIRECTOR",[17,22],{"name":18,"role":19,"phone":20,"phoneExt":10,"email":21},"Alnylam Clinical Trial Information Line","CONTACT","1-877-ALNYLAM","clinicaltrials@alnylam.com",{"name":18,"role":19,"phone":23,"phoneExt":10,"email":21},"1-877-256-9526",[25,38,46,54,62,70,78],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":10},"Clinical Trial Site","RECRUITING","Iowa City","Iowa","52242","United States",{"type":33,"coordinates":34},"Point",[35,36],-91.53017,41.66113,{"lat":36,"lon":35},{"facility":26,"status":27,"city":39,"state":10,"zip":10,"country":40,"cosmosGeoPoint":41,"geoPoint":45,"contacts":10},"Nantes","France",{"type":33,"coordinates":42},[43,44],-1.55336,47.21725,{"lat":44,"lon":43},{"facility":26,"status":27,"city":47,"state":10,"zip":10,"country":48,"cosmosGeoPoint":49,"geoPoint":53,"contacts":10},"Münster","Germany",{"type":33,"coordinates":50},[51,52],7.62571,51.96236,{"lat":52,"lon":51},{"facility":26,"status":27,"city":55,"state":10,"zip":10,"country":56,"cosmosGeoPoint":57,"geoPoint":61,"contacts":10},"Pavia","Italy",{"type":33,"coordinates":58},[59,60],9.15917,45.19205,{"lat":60,"lon":59},{"facility":26,"status":27,"city":63,"state":10,"zip":10,"country":64,"cosmosGeoPoint":65,"geoPoint":69,"contacts":10},"Groningen","Netherlands",{"type":33,"coordinates":66},[67,68],6.56667,53.21917,{"lat":68,"lon":67},{"facility":26,"status":27,"city":71,"state":10,"zip":10,"country":72,"cosmosGeoPoint":73,"geoPoint":77,"contacts":10},"Lisbon","Portugal",{"type":33,"coordinates":74},[75,76],-9.1498,38.72509,{"lat":76,"lon":75},{"facility":26,"status":27,"city":79,"state":10,"zip":10,"country":80,"cosmosGeoPoint":81,"geoPoint":85,"contacts":10},"Madrid","Spain",{"type":33,"coordinates":82},[83,84],-3.70256,40.4165,{"lat":84,"lon":83},{"type":87,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100442360",false,"NCT05040373","Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program","Patisiran-LNP Pregnancy Surveillance Program","Inclusion Criteria:\n\n* Documentation that the patient was exposed to patisiran-LNP at any point starting from 12 weeks before LMP or at any point during pregnancy\n\nExclusion Criteria:\n\n* There are no exclusion criteria for participation in this program.","FEMALE",{"count":96,"type":97},10,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal\u002Fneonatal\u002Finfant outcomes in women exposed to patisiran-LNP.",[101,102],"Hereditary Transthyretin-mediated (hATTR) Amyloidosis","Polyneuropathy",[104,105,106,107,108],"Hereditary neuropathic amyloidosis","Familial amyloidosis","Amyloidosis","Amyloidosis senile","Cardiac amyloidosis","2026-05-28",{"date":111,"type":112},"2026-06-01","ACTUAL",{"date":114,"type":112},"2020-08-01",{"date":116,"type":97},"2030-10-12",{"name":5,"class":6},7]